Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored 

Paul Prescott Just Put Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) On Tomorrow’s Watchlist—Thursday, March 5, 2026

Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly 

To Your Phone. Up To 10X Faster Than Email.

My Full Coverage On (CTXR) Will Start Early

Pull Up (CTXR) Before Tomorrow Morning…

March 4, 2026

Thursday’s Watchlist | See Why (CTXR)Just Hit Tomorrow’s Radar

Dear Reader,

A major shift is unfolding across biotech right now—and it’s changing how quickly a little-known company can move from development headlines to real commercial traction.

For years, the biggest moments in this space centered on trial readouts and FDA decisions.

But the story changes when a company proves it can do what most never reach: launch, distribute, and start generating real revenue.

That transition is rare, difficult, and often the moment broader market attention begins to build.

And today, one name just checked an important box that the Street tends to watch closely.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) recently reached a significant inflection point, reporting its first-ever product revenue following a major year-end launch.

With a pipeline aimed at large, high-value medical markets with significant unmet need—and a newly commercialized oncology asset—the company is positioning itself as an increasingly relevant player across critical care and oncology.

That’s why (CTXR) will be topping our watchlist tomorrow morning—Thursday, March 5, 2026.

But keep in mind, (CTXR) has less than 22M shares listed as available to the public. When companies have small public floats like this, the potential exists for big moves if demand begins to shift.

Right now, (CTXR) is sitting below $1 and appears to be flying under the radar of many screens.

On the analyst front, Jason Kolbert of D. Boral Capital recently reiterated a $6 target, which suggests over 600% upside potential from the current $0.80 range.

His view reflects the value of the company’s oncology ownership and the potential impact of late-stage programs like Mino-Lok as they progress through remaining regulatory steps.

Now let’s take a closer look at what (CTXR) has in hand today—and why the combination of a newly launched asset and late-stage programs has caught our attention.

A Late-Stage Platform With Commercial Momentum

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceuticalleader focused on developing and commercializing first-in-class critical care products.

The company’s strategy centers on high-value, proprietary formulations that address specific gaps in the current healthcare system, particularly in oncology and infectious diseases.

Currently, (CTXR) holds an approximately 74.8% ownership stake in its oncology subsidiary, which recently reached a pivotal commercial turning point.

The company’s focus is on “first-in-class” solutions, meaning they are not merely seeking to improve upon existing treatments but are aiming to provide the first FDA-approved prescription options for specific indications.

This distinctive approach allows (CTXR)to operate in markets with limited competition and high barriers to entry.

In December 2025, the company’s oncology subsidiary officially launchedLYMPHIR, a targeted immunotherapy designed for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

This launch represents the culmination of years of development and marks the transition of (CTXR) from a pure research entity into a revenue-generating company.

Beyond oncology, the company maintains a robust pipeline featuring Mino-Lok, a solution for catheter-related infections, and Halo-Lido, a topical treatment for hemorrhoids.

By focusing on therapeutic areas with limited competition, (CTXR) aims to capture significant shares of niche but lucrative medical markets.

The leadership team, bolstered by decades of experience in the pharmaceutical space, has systematically navigated the regulatory landscape to bring these products to the doorstep of commercialization.

Commercial Execution and Pipeline Expansion

The primary driver for (CTXR) at the start of 2026 is the commercial rollout of LYMPHIR. In February 2026, the company announced it had generated $3.9M in revenue from initial sales in December 2025 alone.

This rapid start suggests a strong initial uptake in the medical community for this CTCL treatment.

The oncology subsidiary estimates the addressable U.S. market for LYMPHIR to be over $400M, providing a substantial runway for growth as the product gains wider adoption among oncologists.

This revenue stream is critical as it provides a proof-of-concept for the company’s ability to market and sell complex biologics effectively.

Market Landscape And Industry Trends

The oncology landscape continues to shift toward targeted immunotherapies that aim to deliver strong efficacy with fewer side effects than traditional chemotherapy.

LYMPHIR aligns with this trend as a targeted approach in a treatment-experienced patient population.

At the same time, critical care—particularly hospital-acquired infections—remains an area where better solutions are still needed.

(CTXR) is addressing this through Mino-Lok, which is designed to salvage central venous catheters in patients with bloodstream infections. Today’s standard of care often requires painful and costly catheter removal and replacement.

By offering a catheter-salvage approach, Mino-Lok is positioned within a market the company cites as exceeding $2B globally, including over $1B in the U.S.

The economic incentive for hospitals to adopt Mino-Lok is clear: reducing the number of surgical procedures and the length of hospital stays. This alignment of patient outcomes and hospital economics is a cornerstone of the (CTXR) business model.

As healthcare systems worldwide look to optimize costs while improving care, Mino-Lok stands out as a high-value asset that could redefine the standard of care for millions of patients annually.

Competitive Positioning and Recent Operational Achievements

(CTXR) has secured a formidable position by targeting “orphan” indications and niche medical needs that larger pharmaceutical companies often overlook.

This strategy has led to the successful completion of a pivotal Phase 3 trial for Mino-Lok, which met both its primary and secondary endpoints.

Meeting these endpoints in a Phase 3 trial is a significant de-risking event for the company, as it demonstrates clinical efficacy and safety at a scale required for FDA approval.

In addition to its clinical successes, (CTXR) has demonstrated savvy financial management. In February 2026, the company secured $3.8M in non-dilutive capital through the New Jersey Economic Development Program.

This program allows technology and life sciences companies to sell their net operating losses and research and development tax credits for cash.

By utilizing this program, (CTXR) has been able to fund its continued execution without diluting existing shareholders, a move that reflects a commitment to long-term value creation.

Pipeline and Product Roadmap Drivers

While LYMPHIR and Mino-Lok are the current headliners, the potential of Halo-Lido should not be underestimated.

Targeting the symptomatic relief of hemorrhoids, this formulation addresses a massive patient population.

Over 10M people in the U.S. report symptoms, yet there is a glaring absence of FDA-approved prescription products that combine a corticosteroid and an anesthetic.

(CTXR) completed a Phase 2b trial for this program in 2023 and is currently working with the FDA to outline the next steps for a Phase 3 study.

The company’s roadmap is clear:

• Maximize the commercial rollout of LYMPHIR via its oncology subsidiary.
• Advance Mino-Lok through the final stages of the NDA process with the FDA.
• Initiate Phase 3 trials for Halo-Lido to capture the massive outpatient market.

This three-pronged approach ensures that (CTXR) has multiple paths to significant valuation growth over the next 12 to 24 months.

Each program targets a different segment of the healthcare market, providing a balanced portfolio that mitigates the risks inherent in any single drug development program.

Financial Position and Management Team

Financially, (CTXR) is in a transition phase, moving from heavy R&D spending to a model supported by product sales.

As of its fiscal year 2025 report, the company has focused on maintaining a lean operational structure while directing resources toward its most promising assets.

The leadership team is a key component of the company’s strength. Leonard Mazur, Chairman and CEO, is a prominent figure in the pharmaceutical industry with a track record of building successful companies and executing high-value exits. Myron Holubiak, Vice Chairman, previously served as President of Roche Laboratories, bringing top-tier institutional knowledge to this agile organization.

7 Reasons Why (CTXR) Will Be Topping Our Watchlist Tomorrow Morning—Thursday, March 5, 2026…

1. Small Float: fewer than 22M shareslisted as available to the public means (CTXR) can react quickly when demand begins to build.

2. Analyst Target: coverage from D. Boral Capital includes a reiterated $6 target, placing (CTXR) at levels that suggest more than 600% upside potential from its recent $0.80 range.

3. Commercial Launch: a major milestone arrived when LYMPHIR became commercially available in December 2025, marking the shift of (CTXR) into a revenue-generating company.

4. First Revenue: early commercialization progress has begun as (CTXR) reported $3.9M from initial LYMPHIR sales following its December 2025 launch.

5. Phase 3 Success: strong clinical data was established after the Mino-Lok program met both primary and secondary endpoints in a pivotal Phase 3 trial tied to catheter-related infections.

6. Large Markets: major healthcare demand areas are being addressed as (CTXR) pursues indications tied to a $400M CTCL market and a catheter infection market exceeding $2B globally.

7. Pipeline Depth: multiple late-stage programs remain in motion with LYMPHIR commercialization underway while (CTXR) advances Mino-Lok regulatory steps and Halo-Lido Phase 3 planning.

Pull Up (CTXR) Before Tomorrow Morning…

Taken together, the pieces surrounding (CTXR) create a story worth paying attention to. The company has already crossed an important threshold with the commercial launch of LYMPHIR and the first reported revenue tied to that rollout.

At the same time, fewer than 22M shares listed as available to the public means activity can become more reactive when attention increases.

Add in a reiterated $6 analyst targetfrom D. Boral Capital, recent Phase 3 success for the Mino-Lok program, and additional late-stage work underway with Halo-Lido, and it becomes clear why (CTXR) could start to appear on more screens.

Beyond those developments, the company is working in areas tied to meaningful healthcare demand—from a CTCL market estimated around $400Mto catheter-related infection treatment markets that exceed $2B worldwide.

With commercialization now underway and several programs advancing toward their next milestones, the coming months could prove to be an important period for (CTXR).

We will have all eyes on (CTXR)tomorrow morning.

Take a look at (CTXR) before you call it a night.

Also, keep a lookout for my morning update.

Have a good night.

Sincerely,

Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter

Street-Ideas.com (“Street-Ideas” or “SI” ) is owned by 147 Media LLC, a single member limited liability company. Data is provided from third-party sources and SI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.

Pursuant to an agreement between 147 Media LLC and TD Media LLC, 147 Media LLC has been hired for a period beginning on 03/04/2026 and ending on 03/05/2026 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, TD Media LLC has paid 147 Media LLC eight thousand seven hundred fifty USD (“Funds”). To date, including under the previously described agreement, 147 Media LLC has been paid thirty three thousand seven hundred fifty USD (“Funds”). These Funds were part of the fifty five thousand USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.

Neither 147 Media LLC, TD Media LLC and their member own shares of (CTXR:US).

Please see important disclosure information here: https://street-ideas.com/disclosure/ctxr-C7PxT/#detailsStreet Ideas6586 W Atlantic AveUnit #2086Delray Beach, FL 33446UnsubscribeUpdate Profile | Constant Contact Data NoticeSent by paul@street-ideas.com